Physician profile
Anthony D Sharp
NPI 1376873281
$11,336.44
in general payments reported to CMS, 2019-2025
22 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,146 · 2022: $2,697 · 2023: $1,755 · 2024: $2,537 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,144 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,143.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $5,606.17 | 2021-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $2,132.22 | 2021-2025 | |
| Genzyme Corporation | $683.24 | 2023-2025 | |
| Biogen, INC. | $571.18 | 2021-2025 | Tysabri, Vumerity |
| Celgene Corporation | $411.36 | 2022-2025 | Zeposia |
| Tg Therapeutics, INC. | $279.42 | 2023-2025 | |
| Horizon Therapeutics Plc | $248.82 | 2022 | |
| Avanir Pharmaceuticals, INC. | $204.44 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $195.07 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $191.56 | 2024-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $171.39 | 2021-2025 | Ajovy, Austedo Xr |
| Abbvie INC. | $120.88 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $119.75 | 2022-2025 | Soliris |
| Janssen Pharmaceuticals, INC | $102.97 | 2021 | |
| Genentech USA, INC. | $79.87 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $62.60 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $45.31 | 2023 | Nuedexta |
| Genentech, INC. | $29.25 | 2025 | Ocrevus |
| Piramal Critical Care | $24.04 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.76 | 2022 | |
| Pfizer INC. | $20.35 | 2024 | |
| Amneal Pharmaceuticals LLC | $12.79 | 2023 | Lioresal (Baclofen) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.